Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Details
News Market Reaction – ARVN
On Nov 26, the day this news came out, ARVN closed 2.48% above the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- Conference edition
- 37th annual
- Piper Sandler Healthcare Conference
- Presentation time
- 11:00 a.m. ET
- Scheduled for Thursday, December 4, 2025
Historical Context
-
Management scheduled a Piper Sandler fireside chat with webcast access.
-
Multiple vepdegestrant abstracts accepted for presentation at SABCS 2025.
-
Q3 2025 results with pipeline progress and NDA acceptance for vepdegestrant.
-
Preclinical ARV-393 data to be presented at the ASH 2025 meeting.
-
Participation in Guggenheim and Jefferies healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York.
A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.